May 2011 Issue
Rather than helping, could the current brand of pharmaceutical Quality by Design be acting as a distraction and deterrent to quality?
At the core of missed opportunities in pharma QC/QA is a subtle misunderstanding of the real intent of Lean.
To manage increasingly complex supplier networks, pharmaceutical companies must develop new capabilities, organizational structures and management tools.
Research suggests that a dysfunctional relationship between regulator and regulated is delaying pharmas progress.
With FDA and the Obama administration on alert, it is drug manufacturers' turn to address a crisis.
The scientists who design biopharma products tend to be the same as those who analyze them.
With all the online green manufacturing resources, theres no excuse not to.
Smart phones and similar devices are pushing the wireless envelope, but wireless process control still faces traditional hurdles.
Elan's head of manufacturing, Kevin Brady, talks about what works, and why.
At PDA 2011, at issue was whether current EMA guidelines are rational or risky; also, a look at new filtration products on the market.